Health & Fitness
Health and Fitness
Health and Fitness
Fri, February 13, 2009
Thu, February 12, 2009 I-Flow Will Present at the Roth Capital Partners 2009 OC Conference Wednesday, February 18, 2009 at 4:00 p.m. PST
LAKE FOREST, Calif.--([ BUSINESS WIRE ])--I-FLOW CORPORATION (NASDAQ:IFLO) announced today that it will address institutional shareholders at the Roth Capital Partners 2009 OC Growth Stock Conference on Wednesday, February 18, 2009 at 4:00 p.m. PST.
The Roth Capital Partners Conference will take place February 16-18 at the Ritz Carlton Hotel, Dana Point, CA. Donald M. Earhart, I-Flow's Chairman, President, and Chief Executive Officer will make a presentation featuring the Company's growth strategies and market opportunities.
I-Flow Corporation is a leader in better clinical and economic outcomes because the company's flagship product line, ON-Q® Pain Relief System, reduces narcotic use while relieving pain after surgery so patients get home faster. Hospitals today are reeling from financial, economic and government pressures that present unique opportunities for ON-Q. Through the use of strong clinical study findings and ongoing evidence-based medicine results, ON-Q can help hospital administrators implement a facility-wide initiative to reduce length of stay, lower cost per discharge and contain costs. The company is redefining recovery following surgery with its novel devices and technologies. Supported by strong clinical evidence, ON-Q is labeled to significantly reduce narcotic intake and to significantly relieve pain better than narcotics alone following surgery. Lowering narcotic intake means patients may have less immunosuppression which may also lead to a lower risk of infection.
ON-Q is a portable and patient-friendly device that automatically and continuously infuses a local anesthetic (pain-numbing medicine) to the surgical site area or adjacent nerves in the days following surgery. Medication is delivered through a proprietary catheter that evenly distributes medication only to the areas that need it, helping patients get back to normal faster. With its robust product portfolio and acquisition of AcryMed in February 2008, I-Flow is rapidly evolving into an acute care products company.
You can access a live webcast and slides of the presentation, after registration, from the Investors link or the Investors' Event Calendar link at [ www.IFLO.com ]. The webcast will be available for replay at approximately 4:30 p.m. PST at this same internet address for approximately 90 days.
About I-Flow
I-Flow Corporation ([ www.IFLO.com ]) designs, develops and markets technically advanced, low cost drug delivery systems and services that are redefining the standard of care by providing life enhancing, cost effective solutions for pain relief.
"Safe Harbor" Statement
Statements by the Company in this press release and in other reports and statements released by the Company are and will be forward-looking in nature and express the Company's current opinions about trends and factors that may impact future operating results. Statements that use words such as "may," "will," "should," "believes," "predicts," "estimates," "projects," "anticipates" or "expects" or use similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to material risks, assumptions and uncertainties, which could cause actual results to differ materially from those currently expected, and readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, the Company undertakes no obligation to publish revised forward-looking statements to reflect the occurrence of unanticipated or subsequent events. Readers are also urged to carefully review and consider the various disclosures made by the Company in this press release that seek to advise interested parties of the risks and other factors that affect the Company's business. Interested parties should also review the Company's reports on Forms 10-K, 10-Q and 8-K and other reports that are periodically filed with or furnished to the Securities and Exchange Commission. The risks affecting the Company's business include, among others: physician acceptance of infusion-based therapeutic regimens; implementation of the Company's direct sales strategy; successful integration of the Company's recent acquisition of AcryMed Incorporated and further development and commercialization of AcryMed's technologies; potential inadequacy of insurance to cover existing and future product liability claims; dependence on the Company's suppliers and distributors; the Company's continuing compliance with applicable laws and regulations, such as the Medicare Supplier Standards and the Food, Drug and Cosmetic Act, and Medicare's and the FDA's concurrence with management's subjective judgment on compliance issues; the reimbursement system currently in place and future changes to that system; product availability, acceptance and safety; competition in the industry; technological changes; intellectual property challenges and claims; economic and political conditions in foreign countries; currency exchange rates; inadequacy of booked reserves; potential non-cash purchase accounting adjustments associated with the AcryMed acquisition; and reliance on the success of the home health care industry. All forward-looking statements, whether made in this press release or elsewhere, should be considered in context with the various disclosures made by the Company about its business.
